Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited


Emcure Pharma IPO Details


Emcure Pharmaceuticals is gearing up for its IPO launch tomorrow, with expectations of raising Rs.1,952 crore through a combination of fresh issue and an offer for sale (OFS). Notably, Namita Thapar, a well-known investor from Shark Tank India and a key member of Emcure Pharmaceuticals' promoter group, stands to generate approximately Rs.127.87 crore by selling around 12.68 lakh shares in the OFS at a price range of Rs.960 to Rs.1,008 per share. Thapar, who currently holds 3.5% of the company's shares, acquired her stake at a weighted average price of Rs.3.44 per share. Additionally, she has been reappointed as a Whole-Time Director for another five years, effective July 28, 2024, following approvals from the board and shareholders.


Alongside Thapar, other promoters such as Satish Ramanlal Mehta, Sunil Rajanikant Mehta, and Samit Satish Mehta, as well as several entities including BC Investments IV and individuals like Pushpa Rajnikant Mehta and Kamini Sunil Mehta, will also participate in the OFS, collectively contributing to the Rs.1,151 crore offer for sale component of the IPO. The funds raised from this IPO will primarily be used to repay existing loans and for general corporate purposes, as outlined in the company's prospectus.


Emcure Pharmaceuticals is recognized for its robust presence in the pharmaceutical industry, specializing in the development, manufacturing, and global distribution of a diverse range of pharmaceutical products across multiple therapeutic areas. Their portfolio includes injectables, biotherapeutics, and oral medications, catering to markets in over 70 countries, with significant operations in Europe, Canada, and India.


The IPO is being managed by Axis Capital Limited, J.P. Morgan India Private Limited, Jefferies India Private Limited, and Kotak Mahindra Capital Company Limited as the book running lead managers, with Link Intime India Private Ltd. serving as the registrar. The grey market premium for Emcure Pharmaceuticals' IPO currently stands at +290, indicating a strong investor appetite with shares trading significantly above the IPO price band. This suggests an anticipated listing price around Rs.1,298 per share, reflecting a 28.77% premium over the upper end of the IPO price range, underscoring investor confidence and market optimism towards the company's prospects.


Posted on : 02-07-2024

Attention Investor

KYC IPO NSE/BSE Mobile
Sukesh Jain Securities Pvt. Ltd. (Member NSE, BSE & CDSL)

BSE Member ID: 6571

NSE Member ID:90327
SEBI Registration No.: INZ000233631
CDSL DP ID: 12080800
SEBI Registration No.: IN-DP-50-2015

Sukesh Jain Commodities Pvt. Ltd.

Sukesh Jain Capital Services Pvt.Ltd


Bank details for fund transfer:-

Sukesh Jain Securities Private Ltd.

IDBI Bank,Rajpur Road,Dehradun

Account No. 0070103000001519

IFSC:- IBKL0000070

HDFC Bank,Rajpur Road,Dehradun

57500001389543

IFSC:- HDFC0000225

Attention Investors

1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. Continuation Sheet

5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

6. Beware of fixed/guaranteed/regular returns/ capital protection schemes. Brokers or their authorized persons or any of their associates are not authorized to offer fixed/guaranteed/regular returns/ capital protection on your investment or authorized to enter into any loan agreement with you to pay interest on the funds offered by you. Please note that in case of default of a member claim for funds or securities given to the broker under any arrangement/ agreement of indicative return will not be accepted by the relevant Committee of the Exchange as per the approved norms.

7. Do not keep funds idle with the Stock Broker. Please note that your stock broker has to return the credit balance lying with them, within three working days in case you have not done any transaction within last 30 calendar days. Please note that in case of default of a Member, claim for funds and securities, without any transaction on the exchange will not be accepted by the relevant Committee of the Exchange as per the approved norms.

8. Check the frequency of accounts settlement opted for. If you have opted for running account, please ensure that your broker settles your account and, in any case, not later than once in 90 days (or 30 days if you have opted for 30 days settlement). In case of declaration of trading member as defaulter, the claims of clients against such defaulter member would be subject to norms for eligibility of claims for compensation from IPF to the clients of the defaulter member. These norms are available on Exchange website at following link :  https://www.nseindia.com/invest/about-defaulter-section.

9. Brokers are not permitted to accept transfer of securities as margin. Securities offered as margin/ collateral MUST remain in the account of the client and can be pledged to the broker only by way of ‘margin pledge’, created in the Depository system. Clients are not permitted to place any securities with the broker or associate of the broker or authorized person of the broker for any reason. Broker can take securities belonging to clients only for settlement of securities sold by the client. 10. Always keep your contact details viz. Mobile number/Email ID updated with the stock broker. Email and mobile number is mandatory and you must provide the same to your broker for updation in Exchange records. You must immediately take up the matter with Stock Broker/Exchange if you are not receiving the messages from Exchange/Depositories regularly.

11. Don't ignore any emails/SMSs received from the Exchange for trades done by you. Verify the same with the Contract notes/Statement of accounts received from your broker and report discrepancy, if any, to your broker in writing immediately and if the Stock Broker does not respond, please take this up with the Exchange/Depositories forthwith.

12. Check messages sent by Exchanges on a weekly basis regarding funds and securities balances reported by the trading member, compare it with the weekly statement of account sent by broker and immediately raise a concern to the exchange if you notice a discrepancy.

13. Please do not transfer funds, for the purposes of trading to anyone, including an authorized person or an associate of the broker, other than a SEBI registered Stock broker.”
.......... Issued in the interest of Investors"